Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | CDC25A | P30304 | 4/20 | 0.39 |
| ▸ | CDC25B | P30305 | 4/20 | 0.39 |
| ▸ | BLM | P54132 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ubiquinone Qo SCHEMBL49420 | 0.92 | HKDC1 (0.61) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| Ubiquinone Qo SCHEMBL2211118 | 0.88 | HKDC1 (0.53) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| Ubiquinone Qo SCHEMBL6760403 | 0.83 | HKDC1 (0.63) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| SCHEMBL10787959 | 0.79 | HKDC1 (0.50) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| SCHEMBL14894669 | 0.77 | ALDH1A1 (0.50) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| Ubiquinone Qo SCHEMBL28073002 | 0.77 | HKDC1 (0.46) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| SCHEMBL11572784 | 0.73 | ALDH1A1 (0.47) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| SCHEMBL1915628 | 0.73 | HKDC1 (0.45) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| Ubiquinone Qo SCHEMBL28257488 | 0.72 | MAPT (0.57) | HKDC1MAPTALDH1A1LMNAAPAF1 | |
| Ubiquinone Qo SCHEMBL29631791 | 0.71 | HKDC1 (0.47) | HKDC1MAPTALDH1A1LMNAAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429511-A2 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | Berg Biosystems, LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2429513-A2 | METHODS FOR TREATMENT OF DISEASE USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | Berg Biosystems, LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2430455-A2 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | Berg Biosystems, LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2430194-A2 | METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | Berg Biosystems, LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2429512-A2 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | Berg Biosystems, LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110123986-A1 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG PHARMA LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110123987-A1 | METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BPGBIO, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110110914-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG, KARA ANN | 2011-05-12 | — | — | US | disclosed |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG LLC | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110914-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | SHMT2, IDH2, GSR | HKDC1 562/4885MAPT 3291/4885ALDH1A1 824/4885 |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | PC, GLS2, PCK2 | HKDC1 186/4885MAPT 1483/4885ALDH1A1 867/4885 |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | SLC25A20, NDUFB10, NDUFA10 | HKDC1 719/4885MAPT 3697/4885ALDH1A1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.